Vyvanse (lisdexamfetamine) is used to treat attention-deficit hyperactivity disorder (ADHD). This drug is more popular than comparable drugs. There are currently no generic alternatives to Vyvanse.
GoodRx has partnered with InsideRx and Shire to reduce the price for this prescription. Check our savings tips for co-pay cards, assistance programs, and other ways to reduce your cost. Vyvanse is covered by most Medicare and insurance plans.
How Vyvanse (lisdexamfetamine) works
Vyvanse (lisdexamfetamine) is an amphetamine stimulant. Researchers don’t know exactly how it works for ADHD, but it increases the activity of the hormones norepinephrine and dopamine in the brain, which improves attention and changes behavior.
What is Vyvanse (lisdexamfetamine) used for?
Attention-deficit/hyperactivity disorder (ADHD) (adults and children aged 6 and over)
Binge eating disorder (adults)
Vyvanse (lisdexamfetamine) dosage forms
Capsule
10mg20mg30mg40mg50mg60mg70mg
Chewable Tablet
10mg20mg30mg40mg50mg60mg
Typical dosing for Vyvanse (lisdexamfetamine)
The typical starting dose for adults and children 6 years of age and older, is 30 mg daily in the morning. The maximum dose is 70 mg. Vyvanse 70 mg for sale


MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.